The National Institute on Drug Abuse (NIDA), one of the components of the National Institutes of Health (NIH), announced its 5th “$100,000 for Start a SUD Startup” Challenge. The Challenge goal is to support research ideas that would further an understanding of Substance Use Disorders (SUD).
Nobilis Therapeutics concept of rapid attenuation of withdrawal symptoms in people with Opioid Use Disorder by on-demand xenon inhalation was spearheaded by Drs. Kaufman and Meloni of Harvard’s McLean hospital. It stems from previous ex-US experience in patients with opioid dependence and the hypothesis that xenon’s neuroinhibitory properties may have strong beneficial short- and long-term effects on opioid withdrawal symptoms.
NIDA expects that the contest will enable participants to test the premise that their research idea will contribute to the pool of innovative small business companies that can successfully compete for NIDA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding.